metaEvidence

	ipilimumab alone	avelumab based treatment	nivolumab based treatment		pembrolizumab based treatment
	Ipilimumab (10 mg/kg)	avelumab alone	nivolumab alone	nivolumab plus SoC	pembrolizumab alone	pembrolizumab plus SoC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive 2
mGC or mGEJC - L1 - HER2 negative 1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive 4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population 4
mGC or mGEJC - L2 - PDL1 positive 1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative 1
mGC or mGEJC - M - HER2 neg/PDL1 positive 1

Comparator: vs Standard of Care (SoC); vs placebo plus SoC; vs placebo; vs paclitaxel;
Risk of bias: low; some concerns; high; NA;